智通财经APP讯，微泰医疗-B(02235)发布公告，预计集团截至2025年12月31日年度的收入将不低于人民币6.50亿元，同比增长约88.1%。预计集团2025年度实现归属于母公司所有者的净利润将不低于人民币3800万元，对比2024年度的人民币-6310万元，增长人民币1.011亿元。
集团于报告期间实现收入大幅增长，成功扭亏为盈，主要受益于：1)集团核心产品之一持续葡萄糖监测系统收入持续强劲增长;2)海外市场拓展成效显著，LinX持续葡萄糖监测系统成功进入多个国家，国际收入同比实现显著增长;3)精益管理持续深化，经营效率显著提升，集团销售费用和管理费用占收入比例实现大幅下降。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.